Profile data is unavailable for this security.
About the company
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
- Revenue in CAD (TTM)0.00
- Net income in CAD-30.00m
- Incorporated2021
- Employees14.00
- LocationSatellos Bioscience Inc200 Bay Street, Suite 2800TORONTO M5J 2J1CanadaCAN
- Phone+1 (647) 660-1780
- Websitehttps://satellos.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZYUS Life Sciences Corp | 465.00k | -33.74m | 50.70m | 2.00 | -- | -- | -- | 109.04 | -0.4505 | -0.4505 | 0.0062 | -0.1659 | 0.0208 | 0.3346 | 1.17 | -- | -150.55 | -74.90 | -454.68 | -102.81 | 13.12 | 3.61 | -7,256.77 | -8,974.20 | 0.0726 | -9.28 | 6.94 | -- | 37.04 | 313.06 | 20.63 | -- | -- | -- |
| Nurexone Biologic Inc | 0.00 | -8.94m | 61.52m | 9.00 | -- | 28.07 | -- | -- | -0.12 | -0.12 | 0.00 | 0.0242 | 0.00 | -- | -- | -- | -208.79 | -215.30 | -263.35 | -529.63 | -- | -- | -- | -- | -- | -102.73 | 0.0514 | -- | -- | -- | -38.58 | -- | -- | -- |
| Sharp Therapeutics Corp | 0.00 | -9.28m | 65.88m | -- | -- | 34.01 | -- | -- | -4.15 | -4.15 | 0.00 | 0.0645 | 0.00 | -- | -- | -- | -435.86 | -- | -512.62 | -- | -- | -- | -- | -- | -- | -- | 0.477 | -- | -- | -- | -2,282.81 | -- | -- | -- |
| Medicenna Therapeutics Corp | 0.00 | -13.82m | 68.40m | 18.00 | -- | 6.68 | -- | -- | -0.1696 | -0.1696 | 0.00 | 0.1228 | 0.00 | -- | -- | 0.00 | -54.21 | -56.44 | -63.31 | -63.20 | -- | -- | -- | -- | -- | -- | 0.0143 | -- | -- | -- | 53.64 | -- | -- | -- |
| Zentek Ltd | 915.32k | -8.19m | 100.00m | 17.00 | -- | 8.34 | -- | 109.25 | -0.0785 | -0.0785 | 0.0088 | 0.1115 | 0.048 | 0.4823 | 5.22 | 53,842.35 | -42.98 | -56.35 | -50.88 | -61.72 | 48.68 | -83.98 | -895.31 | -5,414.02 | 0.5344 | -- | 0.1391 | -- | 2,825.89 | -- | 14.22 | -- | -35.15 | -- |
| Helix Biopharma Corp | 0.00 | -4.88m | 139.77m | 7.00 | -- | 8.70 | -- | -- | -0.0833 | -0.0833 | 0.00 | 0.2104 | 0.00 | -- | -- | -- | -50.07 | -166.45 | -66.34 | -430.79 | -- | -- | -- | -- | -- | -24.39 | 0.0214 | -- | -- | -- | 43.81 | -- | -34.02 | -- |
| Cardiol Therapeutics Inc | 0.00 | -34.78m | 153.00m | 18.00 | -- | 12.53 | -- | -- | -0.4207 | -0.4207 | 0.00 | 0.1093 | 0.00 | -- | -- | 0.00 | -228.34 | -65.44 | -344.00 | -77.84 | -- | -- | -- | -187,932.20 | -- | -- | 0.0138 | -- | -- | -- | -30.39 | -- | -45.03 | -- |
| Satellos Bioscience Inc | 0.00 | -30.00m | 248.12m | 14.00 | -- | 5.32 | -- | -- | -2.31 | -2.31 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -79.17 | -73.24 | -89.12 | -84.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -74.17 | -- | 470.35 | -- |
| NervGen Pharma Corp | 0.00 | -25.82m | 429.71m | 10.00 | -- | -- | -- | -- | -0.3622 | -0.3622 | 0.00 | -0.0401 | 0.00 | -- | -- | -- | -145.30 | -121.67 | -823.55 | -235.16 | -- | -- | -- | -- | -- | -75.72 | -- | -- | -- | -- | -7.25 | -- | -- | -- |
| Eupraxia Pharmaceuticals Inc | 0.00 | -40.18m | 595.22m | 33.00 | -- | 7.27 | -- | -- | -1.12 | -1.12 | 0.00 | 2.43 | 0.00 | -- | -- | 0.00 | -57.28 | -113.52 | -59.04 | -261.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.63 | -- | 70.91 | -- |
